How much funding has Allovir raised?

Allovir has raised $150.0M in total funding, most recently a Series B round.

Who are Allovir's investors?

Allovir's investors include Gilead Sciences, F2 Ventures.

Where is Allovir headquartered?

Allovir is headquartered in Waltham, Massachusetts, United States.

What industry is Allovir in?

Allovir operates in Biotech, Healthcare.

Allovir

Closed

Waltham, United States · Founded 2013 · $150.0M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 51–200
Founded: 2013
Business Model: B2B

Website: allovir.com
Total Funding: $150.0M
Last Round: $120.0M Series BMay 2019
Rounds: 2

About

AlloVir (formerly ViraCyte) was a clinical-stage biopharmaceutical company founded in 2013 out of Baylor College of Medicine's Center for Cell and Gene Therapy, headquartered in Waltham, Massachusetts. The company was the leader in developing allogeneic, off-the-shelf, multi-virus-specific T-cell therapies to restore natural immunity in immunocompromised patients against life-threatening viral diseases. AlloVir was an ElevateBio portfolio company and was publicly traded on Nasdaq. In November 2024, AlloVir and Kalaris Therapeutics announced a merger agreement, effectively ending AlloVir's independent operations.

Summary

Allovir is a Biotech company based in Waltham, United States, founded in 2013. It has raised $150.0M in total across 2 rounds, most recently a $120.0M Series B round in May 2019. Investors include Gilead Sciences and F2 Ventures.